Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.
about
Glycogen synthase kinase 3: more than a namesakeGlycogen synthase kinase 3: a point of convergence for the host inflammatory responseWnt/beta-catenin signaling and small molecule inhibitorsGroup II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt/GSK-3β pathway in adult rat prefrontal cortexTherapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorderThe role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesisCircadian genes, rhythms and the biology of mood disordersChronic over-nutrition and dysregulation of GSK3 in diseasesA new look at an old drug: neuroprotective effects and therapeutic potentials of lithium saltsPlatelet biomarkers in Alzheimer's diseaseDiabetes-associated depression: the serotonergic system as a novel multifunctional targetTargeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesGsk3 Signalling and Redox Status in Bipolar Disorder: Evidence from Lithium EfficacyDual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsGSK3beta in ethanol neurotoxicityLight and electron microscopy study of glycogen synthase kinase-3beta in the mouse brainGSK-3beta is required for memory reconsolidation in adult brainPossible role of the glycogen synthase kinase-3 signaling pathway in trimethyltin-induced hippocampal neurodegeneration in micePrenatal stress down-regulates Reelin expression by methylation of its promoter and induces adult behavioral impairments in ratsDixdc1 is a critical regulator of DISC1 and embryonic cortical developmentAnimal models of bipolar mania: The past, present and future.Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3.Glycogen synthase kinase-3β inhibition in the medial prefrontal cortex mediates paradoxical amphetamine action in a mouse model of ADHD.Mice with a naturally occurring DISC1 mutation display a broad spectrum of behaviors associated to psychiatric disorders.Molecular targets for treating cognitive dysfunction in schizophrenia.Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome.Identification of quantitative trait loci and candidate genes for an anxiolytic-like response to ethanol in BXD recombinant inbred strainsLithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome.Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β)Targeting protein kinases in central nervous system disordersAntipsychotics activate mTORC1-dependent translation to enhance neuronal morphological complexityLithium: a promising treatment for fragile X syndrome.A new avenue for lithium: intervention in traumatic brain injury.Fragile X targeted pharmacotherapy: lessons learned and future directions.GSK3beta: role in therapeutic landscape and development of modulators.Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effectsStructure-based virtual screening of glycogen synthase kinase 3β inhibitors: analysis of scoring functions applied to large true actives and decoy sets.Reactivation of cocaine reward memory engages the Akt/GSK3/mTOR signaling pathway and can be disrupted by GSK3 inhibitionPharmacological and genetic reversal of age-dependent cognitive deficits attributable to decreased presenilin functionRole of the axonal initial segment in psychiatric disorders: function, dysfunction, and intervention
P2860
Q24315635-5914C7BA-EDE6-489E-BB72-CB954EFD81C0Q24597129-D00C4CC6-DD9E-44A0-B568-473AE8955D5CQ24597197-C60C9328-61E1-426C-84E2-8DF9C2CAD27AQ24612550-AD4B29F9-6069-4C75-961C-3A3893D62C9EQ24626017-D64E6B23-9F08-4778-9B7B-C8CB09A9F018Q24651407-870D6FA0-64A8-498B-8175-413F6D78A529Q24669771-CB791E33-9A28-491C-826A-061DE9202884Q26738964-195FC1B4-EEFA-4833-962F-88AD5EE055D4Q26741164-4464E3CD-54E5-460D-A3D6-4BCE9B9F9A09Q26858851-AA162346-3D6B-4A2C-A59C-4ED9245D4665Q26864574-A74C94AE-7184-4487-9746-2B0E9E7400E5Q27023257-C8452F2C-4552-443B-9F47-60BF52A50A0BQ28078551-0A23F99A-B20B-43E4-8508-98A7251D09EDQ28305100-E45B906C-BCB9-4ACC-A261-93335BE42F7DQ28387181-DEFBB69D-F290-49D0-B53C-83249AD2D503Q28472669-F340D97C-F5A9-4C4A-9F31-E0487F409E1CQ28473886-2A76F76D-42AA-4EDD-A030-8F8563886AEFQ28535092-ACFF2879-8DBD-4B1A-AB3E-515F3BB1E0D5Q28543467-C486C4E2-6A65-44AE-B4C4-098048709718Q28588322-BD1C0FA7-9F86-40EB-AF7E-39CC6766F635Q30357298-28F47363-4E41-4009-8476-C13BF47945C0Q30408186-29DA2353-2BC2-4161-8893-1AC421D103E0Q30414710-BFFF4A17-C526-4865-B110-E0B042A98DEFQ30432973-3AD8E746-449A-44A4-B94F-C4EDC62667ACQ30491310-0CBA5AAC-3AD9-4512-B411-381B9971805EQ30500501-85F70A64-1B4F-4AC5-B477-21FE8EC108B2Q30750632-60714FFE-BDA0-4DA5-A5E5-AA373C1834A5Q33607288-01BFC97A-7FDD-46A1-9622-6924B5B74FB2Q33664977-065876DA-6FAD-4A0B-8D50-62C31E040F29Q33671660-24AF45AE-28AE-4EB4-9E24-B54F391622A7Q33777656-352F7E94-7893-412E-B4B9-F39735BEFE3AQ33777951-5F394891-F1DD-4E47-9895-ED3E6593184AQ33777980-6E75D45B-A680-47EC-9800-54B96E58C8A3Q33785983-D9F1ED20-8175-45B9-921A-249FA69AEAF7Q33812730-D661111C-EFDF-40B1-B623-C532CB2228EDQ33929918-5970476D-F657-4F99-8BA6-DFA164CB0D8FQ33934472-2D2832A8-F25A-465A-9501-2B7AF02D7F0BQ33947686-0DAA8EF1-39E5-490B-ACE4-FA0DDD05214EQ34050670-5401457D-4A77-4DBA-8903-2C1707E93A90Q34071914-5A88002A-09ED-4415-8CF5-D5CEC61CA42F
P2860
Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.
@ast
Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.
@en
type
label
Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.
@ast
Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.
@en
prefLabel
Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.
@ast
Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.
@en
P2860
P1433
P1476
Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.
@en
P2093
Myoung-Sun Roh
Richard S Jope
P2860
P304
P356
10.2174/1389450110607011421
P577
2006-11-01T00:00:00Z